On March 24, 2022, InSilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced it has entered into a strategic collaboration with EQRx, a company committed to developing and delivering innovative medicines to patients at radically lower prices. Wilson Sonsini Goodrich & Rosati represented InSilico in the transaction.

The collaboration will combine InSilico's AI-driven platform, Pharma.AI, to advance de novo small molecule design and generation with EQRx's clinical development and commercialization expertise. EQRx and InSilico will engage in a co-development partnership whereby each party will be eligible for a profit share proportional to its respective level of investment. Pursuant to the collaboration agreement, the parties will identify and select up to three therapeutics targets leveraging Pharma.AI. InSilico will lead the drug discovery from small molecule hit identification through lead optimization and preclinical candidate nomination to Investigational New Drug (IND) application. EQRx will assume responsibility for driving clinical development, regulatory activities and commercialization. InSilico has the option to invest in the product candidate(s) at various clinical development stages in return for increased commercialization profits.

The Wilson Sonsini team that advised InSilico on the transaction includes patent attorneys Karen Wong and Richard Wang and technology transactions attorneys Alex Key and Chi-Fei Wang.

For more information, please see the press release.